Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1999-7-14
pubmed:abstractText
Pulse radiolysis was used to generate radicals from one electron reduction of 1,2,4-benzotriazine-1,4-dioxides (derivatives of tirapazamine), and of imidazo [1,2-a]quinoxaline-4-oxides (analogues of RB90740), which have selective toxicity towards hypoxic cells. Radicals from the mono N-oxides (from the latter compounds) react with oxygen approximately 10-40 times faster than does the tirapazamine radical. Radicals from the tirapazamine analogues studied react with oxygen up to approximately 10 times slower than tirapazamine radicals. The quinoxaline N-oxide radicals are involved in prototropic equilibria with pK(a) values (5.5 to 7.4) spanning that reported for tirapazamine (6.0). Generation of radicals radiolytically in the presence of H donors (formate, 2-propanol, deoxyribose) indicate a chain reaction ascribed to H abstraction by the drug radical. The protonated drug radical is much more reactive than the radical anion (H abstraction rate constant approximately equal to 10(2) - 10(3) dm3 mol-1 s-1). Chain termination is ascribed to drug radical-radical reactions, i.e. radical stability in anoxia, with rate constants 2k approximately equal to 1 x 10(7) to 2 x 10(8) dm3 mol-1 s-1 at pH approximately 7.4. Estimates of the reduction potentials of the drug-radical couples in water at pH 7 for two of the mono-N-oxides were in the range-0.7 to 0.8 V vs NHE at pH 7.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-1337838, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-1544841, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-1643639, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-2022346, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-2703405, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-3128984, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-3744945, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-7620216, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-7842137, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-7905907, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-8195029, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-8225020, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-8286012, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-8358728, http://linkedlifedata.com/resource/pubmed/commentcorrection/8763850-8375022
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0306-9443
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S70-4
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Chemical properties which control selectivity and efficacy of aromatic N-oxide bioreductive drugs.
pubmed:affiliation
Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't